ERBB2 and breast cancer: When plotting hazards over time, the observed peak at the two-year time point was less pronounced in HER2-low than in HER2 0 disease regardless of ER status and eventually surpassed that of HER2 0 BC, findings that imply different disease behaviour even within seemingly homogeneous subgroups defined by ER expression.